Mid‑Cap Pharma & Biotech: MDAX Caution, Market‑Access, Patent Cliffs & M&A Insights
Explore how German mid‑cap pharma and biotech firms navigate patent cliffs, market‑access strategies, and M&A to sustain growth in a cautious MDAX‑era.
4 minutes to read






